We also confirmed the strong variability in AUC for Venetoclax response within the group of AML with mutated NPM1 (n = 18, green) by showing two distinct groups at the extremes of CD14+ Monocyte percentages which correlated with BCL-2 protein expression (Fig. 4b). This evidence concerns the gene BCL2 and acute myeloid leukemia.